Cargando…

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases

PURPOSE: This study aimed to evaluate the association between clinical characteristics and development of medication-related osteonecrosis of the jaw (MRONJ) in patients who underwent dental examinations before the initiation of treatment with denosumab or zoledronic acid, which are bone-modifying a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikesue, Hiroaki, Mouri, Moe, Tomita, Hideaki, Hirabatake, Masaki, Ikemura, Mai, Muroi, Nobuyuki, Yamamoto, Shinsuke, Takenobu, Toshihiko, Tomii, Keisuke, Kawakita, Mutsushi, Katoh, Hironori, Ishikawa, Takayuki, Yasui, Hisateru, Hashida, Tohru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236436/ https://www.ncbi.nlm.nih.gov/pubmed/33527228 http://dx.doi.org/10.1007/s00520-021-06018-x

Ejemplares similares

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database
por: Hasegawa, Shiori, et al.
Publicado: (2022)

Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib
por: Ikesue, Hiroaki, et al.
Publicado: (2022)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Denosumab Related Osteonecrosis of Jaw: a Case Report
por: de Sales Lima, Marco Vinícius, et al.
Publicado: (2018)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
por: Limones, Alvaro, et al.
Publicado: (2020)

Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
por: Neuprez, A., et al.
Publicado: (2013)

Zoledronate‐Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma
por: Lundberg, A.P., et al.
Publicado: (2016)

Dental extraction following zoledronate, induces osteonecrosis in rat´s jaw
por: Vidal-Gutiérrez, Ximena, et al.
Publicado: (2017)

Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
por: Tohi, Makiko, et al.
Publicado: (2023)

Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology
por: Alsalih, Aya, et al.
Publicado: (2021)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Evaluation of the usefulness of protocol‐based pharmacist‐facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer
por: Ikesue, Hiroaki, et al.
Publicado: (2020)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma
por: Howie, R. Nicole, et al.
Publicado: (2015)

384. Denosumab-Related Osteonecrosis of the Jaw: an Emergent and Potentially Complex Bone and Joint Infection
por: Bricca, Romain, et al.
Publicado: (2019)

Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
por: Wick, Alexander, et al.
Publicado: (2021)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
por: Fu, Pei-An, et al.
Publicado: (2023)

Platelet-Rich Plasma in Treatment of Zoledronic Acid-Induced Bisphosphonate-related Osteonecrosis of the Jaws
por: Sarkarat, Farzin, et al.
Publicado: (2014)

Geranylgeraniol Restores Zoledronic Acid-Induced Efferocytosis Inhibition in Bisphosphonate-Related Osteonecrosis of the Jaw
por: Chen, Xin, et al.
Publicado: (2021)

Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review
por: Yoshimura, Hitoshi, et al.
Publicado: (2017)

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
por: Yamaoka, Kenta, et al.
Publicado: (2023)

A simplified method for therapeutic drug monitoring of mitotane by gas chromatography‐electron ionization‐mass spectrometry
por: Ando, Motozumi, et al.
Publicado: (2020)

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review
por: de Oliveira, Camila-Carvalho, et al.
Publicado: (2016)

Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases
por: Tofé, Victoria I., et al.
Publicado: (2020)

An Approach for the Prevention, Diagnosis, and Treatment of Jaw Osteonecrosis: Report of a Case Associated with Zoledronic Acid
por: de Alexandria Santos, Danila S., et al.
Publicado: (2020)

Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19
por: Tamura, Ryo, et al.
Publicado: (2023)

Association between 25-hydroxyvitamin D levels and COVID-19 severity
por: Takase, Tomoki, et al.
Publicado: (2022)

Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case
por: Qaisi, Mohammed, et al.
Publicado: (2016)

A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva(®)) Related Osteonecrosis of the Jaw: A Retrospective Study
por: Assili, Zineb, et al.
Publicado: (2021)

Zoledronate treatment duration is linked to bisphosphonate‐related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis
por: Messer, Jonathan G., et al.
Publicado: (2019)

A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw
por: Bullock, George, et al.
Publicado: (2022)

Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: a Histological Evaluation
por: Moradi, Saeed, et al.
Publicado: (2023)

Osteonecrosis of the Jaw
por: Lončar Brzak, Božana, et al.
Publicado: (2023)

Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication
por: Tanaka, Fumiaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_punci8nn6rqf14ictj87ros1go